Memantina Tecnigen (Memantine Hydrochloride)

Memantine hydrochloride acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium influx caused by prolonged glutamate activity. This reduces excitotoxic neuronal damage and supports synaptic function, which can help mitigate cognitive decline in Alzheimer’s disease.

The appropriate dose of Memantina Tecnogen is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to individual needs.

Safety of memantine hydrochloride in pregnancy and lactation has not been established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While both classes aim to improve cognition, memantine targets excitotoxic pathways, and it is typically used in moderate to severe stages, often in combination with other agents for broader symptom control.

Memantina Tecnogen should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless instructed otherwise.

Serious risks include seizures, significant arrhythmias, severe allergic reactions such as anaphylaxis, hallucinations, suicidal thoughts, and hepatic dysfunction. Patients should be monitored closely for any of these events, and treatment should be discontinued if they occur.

Memantina Tecnogen is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in combination with other NMDA antagonists.